EU/3/07/440

Table of contents

About

On 20 March 2007, orphan designation (EU/3/07/440) was granted by the European Commission to The Matthews Consultancy Ltd, United Kingdom, for recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene for the treatment of congenital alpha-1 antitrypsin deficiency.

The Matthews Consultancy Ltd changed its name to TMC Pharma Services Ltd in October 2009.

The sponsorship was transferred to Diamond Roc EOOD, Bulgaria, in April 2019.

The sponsorship was transferred to Diamond Pharma Services Ireland Limited in February 2020.

Key facts

Active substance
Recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene
Disease / condition
Treatment of congenital alpha-1 antitrypsin deficiency
Date of first decision
20/03/2007
Outcome
Positive
EU designation number
EU/3/07/440

Sponsor's contact details

Diamond Pharma Services Ireland Limited 
Coliemore House
Coliemore Road
Dalkey
Co. Dublin
Ireland 
Tel. 02039119410
E-mail: mgraham@diamondpharmaservices.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating